AUSTIN, Texas— Recently, Devin Garza, M.D., a surgeon affiliated with the Texas Institute for Robotic Surgery at St. David’s North Austin Medical Center, was the first gynecologist in the nation to pilot the use of the Acessa™ Procedure with the robotic platform as a combination therapy to treat fibroids. This new minimally invasive therapy enables a woman to obtain relief from fibroid symptoms while avoiding a hysterectomy and keeping her uterus intact.
The Acessa™ Procedure is a surgery performed under anesthesia, using small incisions and a special ultrasound probe to locate the patient's fibroids with high precision in the abdominal cavity. Each fibroid is treated individually with safe radiofrequency energy. The goal is to reduce the size of the fibroids, and in turn, the symptoms they cause. The robotic platform, when used with the Acessa technique, specifically allows for increased ability to combine the excision and removal of very large fibroids (known as a myomectomy). Myomectomy is traditionally more challenging without the use of the robot.
Dr. Devin Garza will continue to offer the Acessa™ Procedure with the robotic platform as a combination therapy at the new St. David’s Surgical Hospital, a campus of St. David’s North Austin Medical Center. St. David’s Surgical Hospital, which opened on October 19, is currently the only hospital commercially offering this procedure to women in Austin.
Fibroids are benign, non-cancerous tumors in a woman’s uterus that, when symptomatic, can be very painful and cause heavy bleeding; pressure on the bladder or rectum; and abdominal discomfort and distention. According to the National Institutes of Health (NIH), at least 70 percent of women in the U.S. will develop fibroids by age 50. It’s also estimated that up to one half of the 600,000 hysterectomies performed in the U.S. each year are for the treatment of symptoms that are secondary to fibroids.
“This minimally invasive, combination therapy we’ve been piloting provides permanent relief from fibroid symptoms without a hysterectomy,” Thomas Payne, M.D., Executive Medical Director of the Texas Institute for Robotic Surgery, said. “We are proud to work with a team of experts to establish the most comprehensive approach to fibroid treatment and to make this therapy available to other surgeons throughout the nation.”
The Texas Institute for Robotic Surgery—an international treatment, training and research center that combines excellence in robotic-assisted surgery and outcomes with education and training—was launched in March 2011. It houses the world’s largest collective intelligence on robotic surgery, bringing together information on quality, performance and cost from more than 100 hospitals across the United States. It also features an educational epicenter designed to teach best practices to hospital leadership, surgeons and surgical teams involved in the delivery of robotic-assisted surgery.
St. David’s North Austin Medical Center
St. David’s North Austin Medical Center is part of St. David’s HealthCare, one of the largest health systems in Texas, which was recognized with a Malcolm Baldrige National Quality Award in 2014. The 378-bed multi-specialty, acute care facility is dedicated to the highest level of women’s health services, including maternity and newborn care with Level I, II and III nurseries at the adjacent St. David’s Women’s Center of Texas. The facility also features a 24-hour emergency department, the Texas Institute for Robotic Surgery, the Bariatric Center, heart and vascular center, neurology and neurosurgery, a kidney transplant program, inpatient and outpatient surgery, and acute inpatient and outpatient rehabilitation, among many others. St. David’s North Austin Medical Center is also home to St. David’s Children’s Hospital. In 2012, 2013, 2015 and 2016, the hospital earned a national distinction for patient safety from The Leapfrog Group.
About Halt Medical, Inc.
The company is focused on establishing a new standard of care for women with symptomatic uterine fibroids. The Acessa System is cleared by the FDA and has CE mark for use in percutaneous, laparoscopic coagulation and ablation of soft tissue, including treatment of symptomatic uterine fibroids under laparoscopic ultrasound guidance. The Company is located in Brentwood, CA. For information about the Acessa System, please visit www.acessaprocedure.com.